The healthcare sector saw key regulatory and corporate news this week. AstraZeneca received U.S. FDA approval for Baxfendy, a first-in-class drug for treatment-resistant hypertension, which the company expects could become a blockbuster product. Separately, Sino Biopharmaceutical gained conditional approval in China for zongertinib, an oral therapy for a specific type of advanced HER2-mutant lung cancer, addressing a significant unmet need.
In other sector news, medical device firm ConvaTec reported slowed revenue growth for the first four months of 2026. The company maintained its 2026 guidance but warned that rising oil prices could significantly increase input costs in 2027, creating a potential headwind and causing its shares to fall.